Benoı̂t Rousseau
YOU?
Author Swipe
View article: 143 Immune checkpoint blockade in tumors with genomic amplification of <i>PD-L1</i> and <i>PD-L2</i>
143 Immune checkpoint blockade in tumors with genomic amplification of <i>PD-L1</i> and <i>PD-L2</i> Open
View article: Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer
Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer Open
Purpose: Microsatellite stable (MSS) colorectal cancers, in contrast to microsatellite instability–high colorectal cancers, have few mutations and are insensitive to immune checkpoint blockade (ICB). Colorectal cancers treated with targete…
View article: Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors
Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors Open
Background Alteration in metabolic activities is a critical step in cancer progression. Myriad metabolic-based therapy options are increasingly being proposed for human tumours. However, emerging evidence highlights interpatient metabolic …
View article: Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models Open
Hypermutation induced by mismatch repair (MMR) inactivation leads to immune surveillance in colorectal cancer (CRC) and in several other malignancies. We investigated the impact of a rationally designed chemotherapy combination on the gene…
View article: Figure S1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure S1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Supplementary Figure 1
View article: Supplementary Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Supplementary Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Table S1
View article: Figure S3 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure S3 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Supplementary Figure 3
View article: Figure S2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure S2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Supplementary Figure 2
View article: Figure S4 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure S4 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Supplementary Figure 4
View article: The role of recurrent somatic mutations that alter conserved m6A motifs in human cancer
The role of recurrent somatic mutations that alter conserved m6A motifs in human cancer Open
N6-methyladenosine (m6A) is the most abundant internal RNA modification in eukaryotes and plays a key role in cellular growth and development. Global changes in cellular methylated RNA and m6A-mediated transcript regulation significantly i…
View article: The Duration of Immunotherapy for Mismatch Repair–Deficient Cancers
The Duration of Immunotherapy for Mismatch Repair–Deficient Cancers Open
View article: Supplementary Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Supplementary Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Table S1
View article: Figure 3 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure 3 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
OS according to treatment (regorafenib vs. placebo) in patients with chemorefractory mCRC in the CORRECT trial in patients with (A) STC1-low levels or (B) STC1-high levels (optimized cut-off*). *Optimized STC1 plasma levels: …
View article: Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Biomarkers for antiangiogenic drugs in chemorefractory metastatic colorectal cancer (mCRC) are lacking. We investigated the relationship between stanniocalcin 1 (STC1) and outcomes in patients treated with regorafenib in the TEXCAN and COR…
View article: Figure S2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure S2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Supplementary Figure 2
View article: Figure 1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure 1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
OS in patients with refractory mCRC from the TEXCAN study according to baseline plasma protein levels of (A) ANG2 and (B) STC1.
View article: Figure S4 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure S4 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Supplementary Figure 4
View article: Figure S1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure S1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Supplementary Figure 1
View article: Figure S3 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure S3 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Supplementary Figure 3
View article: Table 1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Table 1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
STC1 plasma protein expression in healthy donors and patients with previously untreated mCRC (EPITOPES-CRC02) and in the refractory setting (CORRECT)
View article: Table 2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Table 2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Baseline characteristics of the overall CORRECT cohort and STC1 subgroups (optimized cut-offa)
View article: Figure 2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure 2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
OS according to baseline STC1 plasma levels (optimized cut-off*) in patients with chemorefractory mCRC in the CORRECT study. A, Overall cohort (N = 646). B, Regorafenib cohort (n = 435). C, Placebo cohort…
View article: Data from Analysis of Shared Variants between Cancer Biospecimens
Data from Analysis of Shared Variants between Cancer Biospecimens Open
Purpose:Mutational data from multiple solid and liquid biospecimens of a single patient are often integrated to track cancer evolution. However, there is no accepted framework to resolve if individual samples from the same individual share…
View article: Supplementary Methods1 from Analysis of Shared Variants between Cancer Biospecimens
Supplementary Methods1 from Analysis of Shared Variants between Cancer Biospecimens Open
Supplementary Methods
View article: Supplementary Figures and Tables1 from Analysis of Shared Variants between Cancer Biospecimens
Supplementary Figures and Tables1 from Analysis of Shared Variants between Cancer Biospecimens Open
Supplementary Figures and Supplementary Table Headings
View article: Supplementary Tables1 from Analysis of Shared Variants between Cancer Biospecimens
Supplementary Tables1 from Analysis of Shared Variants between Cancer Biospecimens Open
Supplementary Table Data
View article: Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Biomarkers for antiangiogenic drugs in chemorefractory metastatic colorectal cancer (mCRC) are lacking. We investigated the relationship between stanniocalcin 1 (STC1) and outcomes in patients treated with regorafenib in the TEXCAN and COR…
View article: Analysis of Shared Variants between Cancer Biospecimens
Analysis of Shared Variants between Cancer Biospecimens Open
Purpose: Mutational data from multiple solid and liquid biospecimens of a single patient are often integrated to track cancer evolution. However, there is no accepted framework to resolve if individual samples from the same individual shar…
View article: Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer Open
Patients with POLE/D1pd mCRC showed more favorable outcomes compared to dMMR/MSI-H mCRC to treatment with ICIs in terms of tumor response and survival.
View article: Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signatures
Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signatures Open
Despite the overall efficacy of immune checkpoint blockade (ICB) for mismatch repair deficiency (MMRD) across tumor types, a sizable fraction of patients with MMRD still do not respond to ICB. We performed mutational signature analysis of …